Medical/Pharmaceuticals

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

EPLive 2024 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on co...

2024-03-26 23:58 987

Datasea Enters into 5G AI Multimodal Communication Cooperation Agreement Expected to Expand its China 5G Services Revenue

The Agreement with an Estimated Value of $30 Million Supports its Revenue Guidance of$86 Million, a 1,128% Year-Over-Year Increase for its Full Fiscal Year BEIJING, March 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative ...

2024-03-26 22:00 1376

WuXi Biologics Reports Solid 2023 Annual Results

Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew by 101.7% Y-o-Y "R" in CRDMO Thrived with Extended Part...

2024-03-26 21:53 1890

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

LYON, France, March 26, 2024 /PRNewswire/ -- Reportlinker announces the release of the report "A White Paper To Understand The Market Structure Of Pediatric Pertussis Hexavalent and Combination Vaccines

2024-03-26 21:00 1035

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

- New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO's analysis of tumor microenvironment SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (K...

2024-03-26 21:00 1232

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

* TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episodes as well as for preventing bleeding during surgery or invasive procedures in hemophilia patients with inhibitors * Interim results from an ongoing Phase 1a study in healthy male volunteers will ...

2024-03-26 20:00 1058

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

* MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events * Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of t...

2024-03-26 19:00 1143

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...

2024-03-26 09:57 1446

Scivita Medical Expands Collaboration with Boston Scientific

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Recently, Scivita Medical Technology Co., Ltd. ("Scivita Medical") and Boston Scientific Corporation (NYSE: BSX), a leading global medical technology company, joined hands again to sign an expanded strategic cooperation arrangement.

2024-03-26 09:30 1488

BioDuro-Sundia's Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167

SHANGHAI, March 26, 2024 /PRNewswire/ -- BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has been approved by Korea Food and Drug Administration (MFDS) for Investigational New Drug ...

2024-03-26 08:30 1567

Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction

GEMBLOUX, Belgium, March 25, 2024 /PRNewswire/ -- Full-Life Technologies ("Full-Life"), today announced the recent achievement of its subsidiary "Full-Life Technology Europe" has obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control ("FANC"), auth...

2024-03-26 08:00 1049

Mom Favorite Brand Momcozy Showcases Cutting-Edge Products at Medtrade 2024

NEW YORK, March 25, 2024 /PRNewswire/ -- Medtrade 2024 attendees looking for mom-centric products now have a new option on the Expo Floor,Momcozy . The mom-oriented, global brand is dedicated to provid...

2024-03-25 23:00 1379

Yunkang Announces 2023 Annual Results, Revenue Reaches RMB892 Million

Steps up R&D investment Focuses on precision medicine and intelligent testing sectors HONG KONG, March 25, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year...

2024-03-25 22:54 1909

GenieMD Awarded Frost & Sullivan's 2024 Company of the Year Award for Pioneering Virtual Chronic Disease Management Solutions Through Its Unified Virtual Care Platform

GenieMD offers a comprehensive virtual care platform, integrating telehealth, remote patient monitoring, chronic care management, and AI-driven insights to impact the treatment and management of chronic diseases. SAN ANTONIO, March 25, 2024 /PRNewswire/ -- Frost & Sullivan recently researched th...

2024-03-25 22:31 1559

WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones

* Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022 * Adjusted net profit reached RMB 412 million, an increase of 112% compared with Year 2022 * Total number of integrated projects increased to 143 * 50 new integrated projects signed in 2023 * Number of Phase...

2024-03-25 21:39 2257

GC Genome to Present New Data at AACR 2024

Offering Hope for Enhanced Early Detection and Patient Care in the Battle Against Cancer YONGIN, South Korea, March 25, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that the company will present two poster presentations at the American Association fo...

2024-03-25 21:00 1500

Sirtex Medical Appoints Matt Schmidt as New Chief Executive Officer and Board of Directors Member

WOBURN, Mass., March 25, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the appointment ofMatt Schmidt as chief executive officer and board of directors member, effectiveMarch 25. Since joining Sirtex in 2023, Schmidt...

2024-03-25 20:00 1502

ANNOUNCEMENT OF 2023 ANNUAL RESULTS OF TONG REN TANG TECHNOLOGIES

BEIJING, March 25, 2024 /PRNewswire/ -- Tong Ren Tang Technologies Co. Ltd. (" Tong Ren Tang Technologies" or the "Group", 1666.HK) is pleased to announce the audited consolidated results of the Group for the year ended31 December 2023. In 2023, the Group's revenue amounted to RMB6.77 billion, rep...

2024-03-25 12:47 2157

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today inManila, wi...

2024-03-25 10:00 937
1 ... 81828384858687 ... 610

Week's Top Stories